Genetics reveal key differences between childhood and adult inflammatory diseases

Clinical takeaway: Pediatric-onset immune-mediated inflammatory diseases share important biology with adult disease, but their genetic drivers are not identical. The findings support studying childhood disease on its own terms rather than assuming adult disease models fully apply.

Many inflammatory diseases occur in both children and adults, and treatment approaches for children often draw on evidence from adult disease. New genetic findings suggest that childhood-onset disease is not always simply an earlier version of the same condition. This distinction could eventually influence how pediatric inflammatory diseases are classified and treated.

Researchers analyzed genetic data across 24 pediatric immune-mediated inflammatory diseases, including autoimmune, autoinflammatory, and allergic conditions. They found substantial overlap across childhood diseases and with adult inflammatory disorders, but also genetic differences tied to processes that are particularly active during childhood, including growth, immune development, and interactions between the immune and nervous systems.

That combination of shared and age-specific biology could help explain why childhood-onset inflammatory diseases can differ from adult forms in presentation and disease course. Longer term, genetic information could help distinguish biologically meaningful disease subtypes, identify children at greater risk for persistent or evolving disease, and guide more individualized treatment.

The genetic analysis also highlighted possible therapeutic opportunities. Among 178 genes identified as potential treatment targets, 43 are already targeted by approved or investigational drugs for at least one immune-mediated inflammatory disease. Several involved immune pathways already targeted by existing therapies, suggesting that some drugs could eventually be studied for additional pediatric inflammatory conditions. However, the results do not yet support changes in genetic testing or treatment; potential targets will require validation specifically in children and individual diseases.

“The findings of this research challenge the assumption that pediatric-onset rheumatic and other immune disorders are simply early manifestations of adult diseases, underscoring the need for further research on the interaction between genetic factors and developmental context in disease pathogenesis,” said senior author Hakon Hakonarson, MD, PhD, director of the Center for Applied Genomics at Children’s Hospital of Philadelphia.

Source: Li J, et al. (2026 Aug 10) Ann Rheum Dis. Shared genetic architecture and therapeutic targets across paediatric immune-mediated diseases